Brokerages Set vTv Therapeutics Inc. (NASDAQ:VTVT) Price Target at $53.00

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of equities analysts have recently commented on the stock. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Zacks Research raised shares of vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. BTIG Research reissued a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Finally, Evercore began coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price on the stock.

Hedge Funds Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VTVT. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the fourth quarter worth $221,000. 683 Capital Management LLC bought a new position in vTv Therapeutics during the fourth quarter worth $731,000. Geode Capital Management LLC increased its position in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP increased its position in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares during the period. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Down 0.2%

NASDAQ:VTVT opened at $32.06 on Thursday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The firm has a market cap of $126.32 million, a price-to-earnings ratio of -34.47 and a beta of 0.27. The company’s 50 day moving average is $35.28 and its 200-day moving average is $35.06.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. Research analysts predict that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.